You searched for
Category:
#WeACT
Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
03/09/2024
Past, Present, Future
15/02/2024
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23/06/2023
Solidarity actions to support the people affected by the war
08/04/2022
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
23/06/2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
22/03/2021
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
24/09/2020
Chiesi Group sponsors Parma Capital of Culture 2020
10/01/2020
Paolo Chiesi appointed Honorary Doctor at Karolinska Institutet
10/05/2019
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
03/09/2018
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
04/04/2018
New study published in The Lancet shows Trimbow® (beclometasone/formoterol/glycopyrronium) superiority over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
15/03/2018
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
22/05/2017
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
20/04/2017